2022
A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome
Güney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak K, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen A, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Advances 2022, 6: 3189-3193. PMID: 35157770, PMCID: PMC9131901, DOI: 10.1182/bloodadvances.2021006018.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaFavorable clinical outcomeB-cell lymphomaPediatric subtypesClinical outcomesLymphomaSubtypes
2020
A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
Mato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.Peer-Reviewed Original ResearchB-cell lymphomaChronic lymphocytic leukemiaLarge B-cell lymphomaR DLBCLStem cell transplantDuration of responseRichter transformationCombination therapyPrior therapyUnmet medical needTriple combinationPrimary endpointOverall survivalF. Hoffmann-La RocheMedian age 71 yearsMedical needTyrosine kinase inhibitor monotherapyDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaIndolent B-cell lymphomaAdvisory CommitteeMajor unmet medical needDiffuse large B-cell lymphomaHoffmann-La RochePhase ICost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCLPevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, Barth M, Hernandez‐Ilizaliturri F. Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem 2020, 1: 122-132. PMID: 33073261, PMCID: PMC7566777, DOI: 10.1002/jha2.2.Peer-Reviewed Original ResearchActivated B cellsPre-clinical modelsSmall molecule inhibitorsClass NEDD8-activating enzyme (NAE) inhibitorEnzyme inhibitorsSCID mouse xenograft modelDiffuse large B-cell lymphomaCell linesLarge B-cell lymphomaActivity of cytarabineCytotoxic chemotherapy agentsFurther clinical studiesB-cell lymphomaViable therapeutic strategyMouse xenograft modelMolecule inhibitorsB-cell lymphoma cell linesDLBCL cell linesGCB-DLBCL cell linesLarge B-cell lymphoma cell linesAugments efficacyChemotherapy agentsClinical studiesLymphoma cell linesMonotherapy controlsOutcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances 2020, 4: 253-262. PMID: 31945157, PMCID: PMC6988401, DOI: 10.1182/bloodadvances.2019000875.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapyProgression-free survivalIntensive immunochemotherapyB-cell lymphomaOveral survivalDHL patientsR-CHOPCR rateEntire cohortAggressive large B-cell lymphomaLarge B-cell lymphomaHigh-risk cytogeneticsOutcomes of patientsLower CR rateMulticenter retrospective studyDouble-hit lymphomaOverall response ratePaucity of dataIFRT groupStandard therapyRetrospective studyRadiation therapyTreatment groupsBCL6 rearrangementsPatients
2018
Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers
Kothari S, Li S, Medeiros L, Ayers E, Landsburg D, Bond D, Maddocks K, Giri A, Hess B, Pham L, Advani R, Liu Y, Barta S, Vose J, Churnetski M, Cohen J, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski A, Lee S, Hill B, Burns T, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri F, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. Blood 2018, 132: 451. DOI: 10.1182/blood-2018-99-111530.Peer-Reviewed Original ResearchInvolved field radiation therapyAggressive large B-cell lymphomaProgression-free survivalLarge B-cell lymphomaOverall response rateB-cell lymphomaDiffuse large B-cell lymphomaExtra-nodal diseaseOverall survivalR-CHOPBristol-Myers SquibbIFRT groupSeattle GeneticsSpeakers bureauCNS prophylaxisDistant relapseCR rateEntire cohortBCL6 rearrangementsStage IMYC rearrangementSimilar progression-free survivalImproved progression-free survivalMulti-center retrospective studyAdvisory Committee